Stockscreener 앱 받기
1.9201
0.20%
-0.0039
시장 영업 전:
1.92
-0.000100
-0.01%
전일 마감가:
$1.924
열려 있는:
$1.95
하루 거래량:
29,857
Relative Volume:
0.37
시가총액:
$6.53M
수익:
$960.60K
순이익/손실:
$-7.10M
주가수익비율:
-0.254
EPS:
-7.56
순현금흐름:
$-8.00M
1주 성능:
-7.24%
1개월 성능:
+4.35%
6개월 성능:
-46.96%
1년 성능:
-70.33%
1일 변동 폭
$1.90
$2.00
1주일 범위
$1.90
$2.10
52주 변동 폭
$1.68
$14.83
Soligenix Inc Stock (SNGX) Company Profile
명칭
Soligenix Inc
전화
609-538-8200
주소
29 EMMONS DRIVE, PRINCETON
SNGX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SNGX
Soligenix Inc
|
1.9201 | 6.53M | 960.60K | -7.10M | -8.00M | -7.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Soligenix Inc Stock (SNGX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2020-07-28 | 다운그레이드 | Dawson James | Buy → Neutral |
| 2018-01-31 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2017-08-14 | 재확인 | Maxim Group | Buy |
| 2017-07-17 | 개시 | H.C. Wainwright | Buy |
Soligenix Inc 주식(SNGX)의 최신 뉴스
Geode Capital Management LLC Has $71,000 Stake in Soligenix, Inc. (NASDAQ:SNGX) - Defense World
Soligenix (NASDAQ: SNGX) HyBryte(TM) Paves Way for Breakthrough Treatment for Rare Skin Cancer - The Globe and Mail
Soligenix (SNGX) Projected to Post Quarterly Earnings on Friday - Defense World
U.S. Severe Oral Mucositis Market Projected To Witness - openPR.com
Press Release Distribution & PR Platform - ACCESS Newswire
Soligenix reports positive results in skin cancer treatment trial By Investing.com - Investing.com India
Fireside Chat with Christopher Schaber, Chief Executive Officer of Soligenix, Inc. - Yahoo Finance
Soligenix reports positive results in skin cancer treatment trial - Investing.com Australia
Solgenix shares rise on positive skin cancer treatment results By Investing.com - Investing.com Canada
Soligenix's HyBryte(TM) Shows 75% Response Rate In Skin Cancer Trial, Backed By FDA Funding - The Globe and Mail
EQS-News: Soligenix's HyBryte(TM) Shows 75% Response Rate In Skin Cancer Trial, Backed By FDA Funding - markets.businessinsider.com
Soligenix (NASDAQ: SNGX) Advances CiVax Amid Ongoing COVID-19 Threat - Barchart.com
Soligenix (NASDAQ: SNGX) Announces Positive Data, Continued Advancement of HyBryte(TM) - The Globe and Mail
Positive Outcome in 75% of CTCL Patients Treated with HyBryte™ f - GuruFocus
SNGX: Updated IIS Data Shows 75% Response Rate and Three Complete Responses… - MSN
Soligenix Announces Positive Data For Extended HyBryte In Early-stage Cutaneous T-cell Lymphoma - Nasdaq
Soligenix (SNGX) Reports Promising Interim Results for HyBryte i - GuruFocus
Positive Outcome in 75% of CTCL Patients Treated with HyBrytetm for 18 Weeks - Lelezard
Soligenix IncPositive Outcome In 75% Of Ctcl Patients Treated With Hybryte For 18 Weeks - marketscreener.com
Positive Outcome in 75% of CTCL Patients Treated with HyBryte™ for 18 Weeks - Finansavisen
Positive Outcome in 75% of CTCL Patients Treated with HyBryte™ for 18 Weeks (PR Newswire) - Aktiellt
Behcet's Disease Market to Show Remarkable Growth Trends from - openPR.com
Behcet’s Disease Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Soligenix, Chugai Pharma, UMC Utrecht, Ganzhou Hemay Pharma, Amgen - The Globe and Mail
Soligenix (NASDAQ: SNGX) Spotlighted In Zacks Small-Cap Research Report, Earns $35 Valuation - Barchart.com
Soligenix (NASDAQ: SNGX) Spotlighted in Zacks Small-Cap Research Report, Earns $35 Valuation - The Globe and Mail
SNGX stock touches 52-week low at $1.74 amid market challenges - Investing.com Canada
SNGX stock touches 52-week low at $1.74 amid market challenges By Investing.com - Investing.com South Africa
Soligenix (NASDAQ: SNGX) Advances Phase 3 Replication Study for Early-Stage Cutaneous T-Cell Lymphoma Treatment - Barchart.com
Zacks Small Cap Decreases Earnings Estimates for Soligenix - The AM Reporter
Zacks Maintains $35.00 Price Per Share Valuation for Soligenix (NASDAQ: SNGX) Amid Promising Vaccine and CTCL Therapy Progress - Barchart.com
Q1 Earnings Forecast for Soligenix Issued By Zacks Small Cap - Defense World
SNGX: Preclinical Data Shows CiVax™ Booster Induces Broad Protection Against COVID-19… - Yahoo Finance
IBN Initiates Coverage of Soligenix Inc. - GlobeNewswire
SNGX: Preclinical Data Shows CiVax Booster Induces Broad Protection Against COVID-19 - Smartkarma
CiVax booster shows broad COVID-19 variant protection By Investing.com - Investing.com South Africa
First National Financial Corporation to Host First Quarter Earnings Call on April 30, 2025 - The Globe and Mail
CiVax booster shows broad COVID-19 variant protection - Investing.com
Soligenix Announces Publication Demonstrating CiVax™ Booster Induces Rapid Broad Protection Against COVID-19 Variants - PR Newswire
Soligenix (NASDAQ: SNGX) Announces Key Milestones and 2024 Financial Results - The Globe and Mail
Soligenix Inc. (SNGX) reports earnings - Quartz
SOLIGENIX, INC. SEC 10-K Report - TradingView
Soligenix Trumps Year-End Financials - Baystreet.ca
Soligenix reports progress and 2024 financials By Investing.com - Investing.com Australia
Soligenix reports progress and 2024 financials - Investing.com India
Soligenix Announces Recent Accomplishments and Year End 2024 Financial Results - Quantisnow
Soligenix Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Soligenix Financial Results Reveal Widening Losses While Clinical Pipeline Expands - StockTitan
Soligenix Inc (SNGX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.39%
3.66%
자본화:
|
볼륨(24시간):